SELECTIVE SEROTONIN REUPTAKE INHIBITORS AND TRICYCLIC ANTIDEPRESSANTS IN COMBINATION - INTERACTIONS AND THERAPEUTIC USES

被引:37
作者
TAYLOR, D
机构
[1] Principal Clinical Pharmacist, Maudsley Hospital
关键词
D O I
10.1192/bjp.167.5.575
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background. The selective serotonin reuptake inhibitors (SSRIs) are now widely used in the treatment of depressive illness. Interest has grown in the use of SSRIs as alternatives to tricyclic antidepressants (TCAs) and in the therapeutic use of combinations of SSRIs and TCAs in refractory depression. Method. MEDLINE and PSYCLit literature searches were conducted. Reference sections from papers retrieved were scrutinised for other relevant reports. Results. Of 41 relevant articles identified, 35 were selected for review. Conclusions. Fluoxetine, fluvoxamine, paroxetine and sertraline may substantially increase TCA plasma levels when given concurrently. Such interactions may give rise to adverse effects. The effect of sertraline may be less profound than that of fluoxetine, fluvoxamine and paroxetine. Limited data suggest that citalopram may not affect TCA serum levels. There is scant literature evidence to support the use of SSRIs in combination with TCAs as a treatment for refractory depression.
引用
收藏
页码:575 / 580
页数:6
相关论文
共 38 条
[1]  
ALDERMAN J, 1994, DESIPRAMINE PHARMACO
[2]  
ARANOW RB, 1989, AM J PSYCHIAT, V146, P911
[3]   RAPID DOWN REGULATION OF BETA-ADRENOCEPTORS BY CO-ADMINISTRATION OF DESIPRAMINE AND FLUOXETINE [J].
BARON, BM ;
OGDEN, AM ;
SIEGEL, BW ;
STEGEMAN, J ;
URSILLO, RC ;
DUDLEY, MW .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1988, 154 (02) :125-134
[4]  
BARROS J, 1993, AM J PSYCHIAT, V150, P1751
[5]  
BAUMANN P, 1993, NORD J PSYCHIAT, V47, P13
[6]   FLUOXETINE INDUCES ELEVATION OF DESIPRAMINE LEVEL AND EXACERBATION OF GERIATRIC NONPSYCHOTIC DEPRESSION [J].
BELL, IR ;
COLE, JO .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1988, 8 (06) :447-448
[7]   MEDICAL COMPLICATIONS OF POLYDIPSIA IN NONPSYCHOTIC DEPRESSION [J].
BENAZZI, F ;
BARTOLINI, F ;
MAZZOLI, M .
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 1994, 39 (03) :185-185
[8]   QUANTIFICATION AND MECHANISM OF THE FLUOXETINE AND TRICYCLIC ANTIDEPRESSANT INTERACTION [J].
BERGSTROM, RF ;
PEYTON, AL ;
LEMBERGER, L .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 51 (03) :239-248
[9]   IMIPRAMINE DEMETHYLATION AND HYDROXYLATION - IMPACT OF THE SPARTEINE OXIDATION PHENOTYPE [J].
BROSEN, K ;
OTTON, SV ;
GRAM, LF .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1986, 40 (05) :543-549
[10]   FLUOXETINE AND NORFLUOXETINE ARE POTENT INHIBITORS OF P450IID6 - THE SOURCE OF THE SPARTEINE DEBRISOQUINE OXIDATION POLYMORPHISM [J].
BROSEN, K ;
SKJELBO, E .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 32 (01) :136-137